We therefore suggest that N19 might represent a new generation of EGFR-TKI or HSP90 inhibitor that act as novel dual inhibitors of EGFR and cMET and efficiently overcome intrinsic and acquired EGFR-TKI resistance in NSCLC cells. Here, EGFR is linked to non-small cell lung carcinoma.